AR and posterior cortical atrophy: However, novel agents such as androgen receptor-targeted agents (ARTAs) have exhibited significant survival benefits in both metastatic and non-metastatic castration-resistant PCa, as well as in metastatic hormone-sensitive PCa [16,17,18].